Sangamo Therapeutics, Inc. SGMO was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $9.28 –$15.65 in the past one-month time frame, witnessed a sharp increase yesterday.
The company has seen four positive estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for Sangamo Therapeutics. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Sangamo Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Sangamo Therapeutics, Inc. Price
Sangamo Therapeutics, Inc. price | Sangamo Therapeutics, Inc. Quote
A better-ranked stock in the Medical - Biomedical and Genetics industry is Aerpio Pharmaceuticals, Inc. ARPO, which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sangamo Therapeutics, Inc. (SGMO) : Free Stock Analysis Report
Aerpio Pharmaceuticals, Inc. (ARPO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research